6533b831fe1ef96bd129851d

RESEARCH PRODUCT

Nephron sparing surgery for renal cell carcinoma with normal contralateral kidney: 25 years of experience.

Rolf GillitzerSebastian W. MelchiorChristian HampelFrederik C. RoosJoachim W. ThüroffSascha Pahernik

subject

NephrologyAdultMalemedicine.medical_specialtyTime FactorsUrologyUrologyNephrectomyRenal cell carcinomaInternal medicinemedicineCarcinomaHumansCystOncocytomaCarcinoma Renal CellAgedAged 80 and overbusiness.industryCancerNephronsMiddle Agedmedicine.diseaseKidney NeoplasmsSurgeryFemalebusinessKidney cancerKidney diseaseFollow-Up Studies

description

We report the long-term results of our consecutive series of 504 patients who underwent NSS for cancer suspicious, solid renal tumors in the presence of a normal opposite kidney at our institution since 1979.A total of 715 patients underwent NSS since 1969, including 504 for an elective indication, that is with a normal opposite kidney. Of these patients 381 (75.6%) had RCC, 123 (24.4%) had cancer suspicious benign lesions, including 53 (10.5%) with oncocytoma, 33 (6.5%) with angiomyo(lipo)ma, 23 (4.6%) with a complicated cyst and 13 (2.8%) with other benign lesions. Of the 381 patients with RCC 283 (74.3%) had clear cell, 68 (17.8%) had papillary and 30 (7.9%) had chromophobic RCC. Mean tumor diameter was 3.0 cm (range 0.5 to 11.0). Mean followup was 6.77 years (range 0.2 to 24.1). The oncological outcome was studied, including pathological features associated with tumor progression.Estimated cancer specific survival rates at 5 and 10 years were 98.5% and 96.7%, respectively. Estimated survival rates free of distant metastasis at 5 and 10 years were 97.5% and 95.1%, respectively. Nine patients with localized RCC experienced local recurrence after NSS. Estimated survival rates free of local recurrence at 5 and 10 years were 98.3% and 95.7%, respectively.The long-term results of our series support the concept of organ sparing surgery for RCC in the presence of a normal opposite kidney with excellent long-term survival and a low tumor recurrence rate.

10.1016/s0022-5347(06)00271-0https://pubmed.ncbi.nlm.nih.gov/16697793